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Ar ticle

Dickkopf-related protein 1 (Dkk1) regulates the
accumulation and function of myeloid derived suppressor
cells in cancer
Lucia D’Amico,1 Sahil Mahajan,1 Aude‑Hélène Capietto,1 Zhengfeng Yang,1 Ali Zamani,1
Biancamaria Ricci,1 David B. Bumpass,1 Melissa Meyer,2 Xinming Su,2 Andrea Wang‑Gillam,2
Katherine Weilbaecher,2,4 Sheila A. Stewart,3,4,5 David G. DeNardo,2,4,5 and Roberta Faccio1,4
Department of Orthopedics, 2Department of Medicine Oncology Division, 3Department of Cell Biology and Physiology, 4Siteman Cancer Center, and 5ICCE Institute,
Washington University School of Medicine, St. Louis, MO 63110

T umor–stroma interactions contribute to tumorigenesis. Tumor cells can educate the stroma at primary and distant sites to
facilitate the recruitment of heterogeneous populations of immature myeloid cells, known as myeloid-derived suppressor cells
(MDSCs). MDSCs suppress T cell responses and promote tumor proliferation. One outstanding question is how the local and
distant stroma modulate MDSCs during tumor progression. Down-regulation of β-catenin is critical for MDSC accumulation
and immune suppressive functions in mice and humans. Here, we demonstrate that stroma-derived Dickkopf-1 (Dkk1) targets
β-catenin in MDSCs, thus exerting immune suppressive effects during tumor progression. Mice bearing extraskeletal tumors
show significantly elevated levels of Dkk1 in bone microenvironment relative to tumor site. Strikingly, Dkk1 neutralization
decreases tumor growth and MDSC numbers by rescuing β-catenin in these cells and restores T cell recruitment at the tumor
site. Recombinant Dkk1 suppresses β-catenin target genes in MDSCs from mice and humans and anti-Dkk1 loses its antitumor
effects in mice lacking β-catenin in myeloid cells or after depletion of MDSCs, demonstrating that Dkk1 directly targets
MDSCs. Furthermore, we find a correlation between CD15+ myeloid cells and Dkk1 in pancreatic cancer patients. We establish
a novel immunomodulatory role for Dkk1 in regulating tumor-induced immune suppression via targeting β-catenin in MDSCs.

Incipient tumor cells that escape intrinsic cellular mechanisms of tumor suppression require support from the surrounding stroma for their growth and ability to metastasize.
The tumor-associated stroma provides vascular support and
protumorigenic factors that can sustain tumor cell growth
(Räsänen and Vaheri, 2010; Barcellos-Hoff et al., 2013).
Similarly, at metastatic sites, such as in the bone microenvironment, tumor-activated osteoclasts and osteoblasts release
bone-derived factors that favor tumor colonization and proliferation (Weilbaecher et al., 2011). In addition to direct
effects on tumor cells, the stromal compartment at primary
and distal sites can indirectly contribute to tumor progression by supporting the development of an immunosuppressive environment that facilitates tumor escape from immune
control (Mace et al., 2013).
Cytotoxic T cells are central players in immune-mediated
control of cancer, and the extent of tumor infiltration by cytotoxic T cells correlates with a favorable prognosis (Galon et al.,
2006; Hamanishi et al., 2007; Mahmoud et al., 2011; Bindea et
al., 2013). However, this natural defense mechanism can be severely blunted by immunosuppressive cell populations, includ-

ing regulatory T cells and myeloid suppressor cells (Schreiber et
al., 2011; Gabrilovich et al., 2012). Among myeloid populations
with a potent ability to suppress antitumor T cell responses,
myeloid-derived suppressor cells (MDSCs) are found in high
numbers in circulation and in the tumor microenvironment
of patients with advanced malignancies (Gabitass et al., 2011).
MDSCs comprise a heterogeneous population of immature
Gr1+/CD11b+ cells in mice and CD33+/CD11b+ in humans
(Gabrilovich et al., 2012). This myeloid population is further
classified into granulocytic or monocytic MDSCs based on the
expression levels of Ly6G and Ly6C, respectively, in the mouse
model or CD15 and CD14 in humans.
Investigations into the mechanisms that drive MDSC
recruitment and activity have shown that GM-CSF, IL-6, and
VEGF play an important role via modulation of Jak–STAT
signaling pathways (Gabrilovich et al., 2001; Trikha and Carson, 2014). In addition to Jak–STAT, we have recently shown
that down-regulation of β-catenin in MDSCs is required for
their accumulation during tumor progression in mice and
cancer patients (Capietto et al., 2013). Specific deletion of
β-catenin in myeloid cells leads to greater s.c. tumor growth
due to the accumulation and higher immune suppressive ef-
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RESULTS
Dkk1 is up-regulated in the bone microenvironment of
mice bearing extraskeletal tumors
We have recently shown that down-regulation of β-catenin
levels in MDSCs occurs in tumor-bearing mice and cancer
patients. Reductions in β-catenin drive MDSC accumulation in the bone marrow, spleen, and at primary tumor sites,
and control their immune suppressive effects (Capietto et al.,
2013). To elucidate the mechanism(s) responsible for reduced
β-catenin levels in MDSCs during tumor progression we
measured the circulating levels of the Wnt/β-catenin inhibitor Dkk1, because it has been associated with poor prognosis
in various types of cancer (Liu et al., 2014). C57BL/6 WT
mice were s.c. injected with 105 Lewis lung carcinoma (LLC)
cells and serum was collected 0, 7, 10, and 14 d later. We
found that circulating Dkk1 levels increased 20-fold, paralleling tumor progression (Fig. 1 A).
828

Next, we wanted to determine the source of Dkk1 in
tumor-bearing mice. Surprisingly, immunohistochemistry
(IHC) analysis of LLC tumors revealed a weak and diffuse
Dkk1 staining compared with pancreatic islets from mice
with pancreatic adenocarcinomas, which we used as a positive control, or the ductal epithelium and stroma, which were
negative and thus used as internal negative control (Fig. 1 B).
This result was unexpected, given the significant increase in
Dkk1 in circulation (Fig. 1 A), and prompted us to investigate
other sources of Dkk1 in the LLC tumor-bearing mice.
Dkk1 is highly expressed in the bone microenvironment by osteoblasts and osteocytes to regulate bone homeostasis (Li et al., 2006; Pinzone et al., 2009). Because MDSCs
originate and accumulate in the bone microenvironment
during tumor progression, we wondered whether Dkk1 levels would be increased in bones from tumor-bearing mice.
First, we measured by quantitative RT-PCR Dkk1 transcripts
in crushed bones devoid of bone marrow cells (as a source
of osteoblasts and osteocytes), and in the bone marrow cells
from LLC tumor-bearing mice. LLC tumors in vivo from the
same cohort of mice and LLC cells cultured in vitro were
used as controls. Confirming the IHC data, the LLC cell line
did not express detectable Dkk1 transcripts. Strikingly, Dkk1
mRNA levels in the crushed bones (devoid of marrow cells)
were ∼500-fold higher compared with the tumor mass and
the bone marrow cells (Fig. 1 C), suggesting that osteoblasts
and osteocytes are a major source of Dkk1 in tumor-bearing
mice. Because Dkk1 is a secreted protein, we measured Dkk1
protein levels in the bone marrow interstitial fluid from LLC
tumor-bearing mice by ELISA to further confirm increased
expression of bone-derived Dkk1 during tumor progression.
We found a significant increase in bone-derived Dkk1 compared with no tumor controls (Fig. 1 D).
To determine whether production of Dkk1 by the
bone microenvironment is observed in other tumors, we
turned to the B16 melanoma model, as β-catenin is also
down-regulated in MDSCs from B16 tumor-bearing mice.
Similar to mice bearing LLC tumors, increased Dkk1 levels
were observed in circulation (Fig. 1 E) and in the bone
microenvironment (Fig. 1, F and G) of animals injected s.c.
with 105 B16 melanoma cells. RT-PCR analysis revealed
no detectable Dkk1 expression in the tumor cells, and the
transcript levels in the tumor mass in vivo were 340-fold less
than in the bone (Fig. 1 F).
Finally, we analyzed Dkk1 mRNA expression in the
bones of tumor-bearing mice (LLC and B16) versus primary
osteoblasts or osteoclasts cultured in vitro (Fig. 1 H).We found
a similar magnitude of expression between crushed bones and
osteoblast cultures, whereas no expression was detected in the
osteoclasts, suggesting that bone-resident osteoblasts, but not
osteoclasts, are a major source of Dkk1 in vivo.
Collectively, these results demonstrate increased levels of
Dkk1 in the circulation and in the bone microenvironment
in two different tumor models, supporting the hypothesis that
Dkk1 might regulate β-catenin levels in peripheral MDSCs.
Role of Dkk1 in cancer | D’Amico et al.
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fects of MDSCs. Conversely, β-catenin stabilization in myeloid
cells limits tumor growth by limiting MDSC numbers and
their T cell suppressive function (Capietto et al., 2013). However, an outstanding question in the field is how β-catenin
is down-regulated in MDSCs during tumor progression and
whether the tumor-associated stromal compartment plays
a role in this process.
Dickkopf-1 (Dkk1) is an inhibitor of the Wnt–β-catenin
pathway (MacDonald et al., 2009). It competitively binds to
the Wnt co-receptors LRP5/6, leading to degradation of the
β-catenin complex. High circulating levels of Dkk1 correlate
with poor prognosis in various cancers (Liu et al., 2014). In
the context of multiple myeloma (MM), Dkk1, produced
by the cancer cells and bone marrow stromal cells, inhibits
osteoblast maturation while enhancing osteoclast resorption (Tian et al., 2003; Fowler et al., 2012). These effects
of Dkk1 on the bone microenvironment contribute to the
development of focal osteolytic lesions and indirectly favor
MM progression. Increased levels of Dkk1 are also found in
serologic samples from patients with cancer of the pancreas,
stomach, liver, lung, esophagus, and breast, regardless of the
presence of metastatic dissemination to bone (Yamabuki et
al., 2007; Liu et al., 2014). These observations suggest more
pleiotropic effects of Dkk1 in controlling tumor growth, independent of its ability to alter the bone microenvironment.
Furthermore, down-regulation of β-catenin in cancerous
cells should reduce their proliferative capacity. Therefore, it
remains to be established why increased levels of Dkk1 correlate with poor prognosis.
We now provide evidence that Dkk1 supports the generation of MDSCs, and thus is a negative regulator of antitumor immune responses. Importantly, we show that Dkk1
neutralization decreases tumor growth and MDSC accumulation in extraskeletal tumor models. To our knowledge, this
is the first demonstration that Dkk1 supports extraskeletal
tumor growth by creating an immunosuppressive environment through direct targeting of β-catenin in MDSCs.

Dkk1 directly targets β-catenin in MDSCs
Dkk1 antagonizes canonical Wnt signaling by binding to
LRP5/6 receptors and inhibiting their interaction with
Wnt ligands. To evaluate whether Dkk1 can directly target
MDSCs, we first measured LRP5 and LRP6 expression levels in Gr1+/CD11b+ cells isolated from tumor naive mice
or animals bearing s.c. LLC tumors. Both receptors were
highly expressed in MDSCs from tumor-bearing mice compared with control mice (Fig. 2 A). Induction of LRP5 and
LRP6 transcripts was also observed in naive Gr1+/CD11b+
cells cultured in vitro in the presence of 10% serum from
tumor-bearing mice to mimic the in vivo setting (Fig. 2 B).
To test whether Dkk1 directly affects β-catenin protein levels in MDSCs, naive Gr1+/CD11b+ cells were isolated from the
bone marrow, cultured as described in the Materials and methods, and stimulated for 3 h with recombinant Dkk1 (rDkk1; 100
ng/ml). Because Dkk1 is elevated in the serum of tumor-bearing
mice (Fig. 1 A), which was added to the culture medium, we also
JEM Vol. 213, No. 5

incubated the cells with anti-Dkk1 (100 ng/ml), an exercise that
would establish the importance of circulating Dkk1 in regulating
β-catenin. Dkk1 neutralization resulted in increased β-catenin
protein levels in the cells (Fig. 2 C). In contrast, treatment with
rDkk1 reduced β-catenin protein levels compared with controls
(Fig. 2 C). Confirming these findings, quantitative RT-PCR
analysis of β-catenin target genes showed a significant reduction
of LEF1,TCF4, and Axin2 mRNA expression levels after rDkk1
stimulation versus untreated controls (Fig. 2 D).
To determine whether Dkk1 reduces β-catenin levels
in human MDSCs, CD33+ myeloid cells were isolated from
PBMCs obtained from different healthy donors and cultured
in the presence of serum from cancer patients with elevated
Dkk1 levels. Cells were incubated with anti-Dkk1 or stimulated with rDkk1, and mRNA levels of the β-catenin target
genes TCF4 and LEF1 were measured. Similar to the mouse
model, we found that rDkk1 reduced the expression of TCF4
and LEF1 (Fig. 2, E and F), whereas neutralization of Dkk1
829

Downloaded from jem.rupress.org on August 28, 2017

Figure 1. Dkk1 is up-regulated in mice bearing extraskeletal tumors. (A) Dkk1 serum levels were measured by ELISA in WT mice on day 0 or 7, 10,
and 14 d after LLC s.c. injection. n = 4 per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Experiment was repeated two times. (B) IHC from mouse pancreatic
ductal adenocarcinoma (CTR) or LLC s.c. tumor sections stained for Dkk1. Images are taken with an 20× objective (left) and 2× magnification is shown on
the right. Data are representative of four different tumor sections. (C) Dkk1 mRNA levels were measured in LLC in vitro, LLC tumor mass, crushed bones
devoid of marrow cells, and bone marrow cells isolated from WT mice 2 wk after s.c. tumor injection. Data are expressed as relative expression to cyclophillin.
Results represent mean ± SD (n = 6, experiment repeated three times). **, P < 0.01; ***, P < 0.001. (D) Dkk1 levels in the bone marrow interstitial fluid of LLC
tumor–bearing mice versus no tumor controls collected 2 wk after s.c. tumor injection. *, P < 0.05. n = 6. Experiment was performed in duplicate. (E) Dkk1
levels in circulation from WT mice prior, 7, or 14 d after s.c. inoculation of 105 B16 cells. *, P < 0.05; ***, P < 0.001. n = 5. Experiment performed in duplicate.
(F) Dkk1 mRNA levels were measured in B16 cell line, tumor mass, crushed bones devoid of bone marrow cells, and in the bone marrow 14 d after B16 s.c.
tumor injection. *, P < 0.05; ***, P < 0.001. n = 5. Experiment was repeated more than three times. (G) Dkk1 levels in the bone marrow interstitial fluid from
WT mice prior and 14 d after s.c inoculation of 105 B16 cells. *, P < 0.05. n = 6. Experiment was performed in duplicate. (H) Dkk1 mRNA levels were measured
in crushed bones separated from the bone marrow of mice inoculated s.c. with LLC or B16 for 14 d, in osteoblast cultures and primary osteoclasts. n = 3.
Experiment was repeated three times.

resulted in the up-regulation of the two β-catenin target
genes in human cells (Fig. 2, G and H). Thus, Dkk1 inhibits
the β-catenin pathway both in mouse and human MDSCs.
Dkk1 expression correlates with MDSC
accumulation in cancer patients
Having demonstrated that Dkk1 directly targets β-catenin
signaling in MDSCs from both mice and humans, we next
830

wanted to determine whether increased Dkk1 expression is
associated with MDSC accumulation in cancer patients. Elevated levels of Dkk1 have been observed in serum and at
the primary tumor sites in pancreatic cancer. Previous studies have also shown that pancreatic cancer patients have expanded CD15+ MDSC populations (Porembka et al., 2012).
We further demonstrated that MDSCs isolated from these patients have decreased β-catenin levels compared with healthy
Role of Dkk1 in cancer | D’Amico et al.
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Figure 2. Dkk1 targets β-catenin in MDSCs and
correlates with CD15 myeloid marker. (A and B)
LRP5 and LRP6 mRNA expression in MDSCs isolated
from LLC tumor-bearing mice 14 d after tumor injection (A), or in Gr1+/CD11b+ naive cells incubated in
vitro in the presence or absence of 10% serum from
tumor-bearing mice (B). Mean ± SD (n = 3 mice/
group) *, P < 0.05; **, P < 0.01. (C) Western blot analysis of β-catenin in Gr1+/CD11b+ naive cells cultured
for 6 h in medium containing 10% serum from tumor-bearing mice in the presence of rDkk1 (100 ng/
ml) or anti-Dkk1 (100 ng/ml). One representative experiment of three is shown. (D) LEF1, TCF4, and Axin2
mRNA levels were measured in cells as in B. Mean ±
SD from three independent experiments. *, P < 0.05.
(E–H) LEF1 and TCF4 mRNA levels were measured in
CD33+ PBMCs isolated from healthy donors, cultured
in the presence of 10% serum from cancer patients
and stimulated in vitro with rDkk1 (100 ng/ml; E and
F) or incubated with anti-Dkk1 (100 ng/ml; G and H).
Representative graphs from seven different donors
are shown. Experiment was repeated more than three
times. (I) Representative IHC from pancreatic cancer
tissues with high or low Dkk1 expression is shown.
CD15 staining, as a marker of granulocytic MDSCs, is
also shown. (J) Correlation between CD15+ cell numbers and Dkk1 pixel density from 55 pancreatic cancer
tissues is shown (Spearman’s r = 0.27; P = 0.04).

donors (Capietto et al., 2013), thus making this tumor model
highly relevant for studying a possible correlation between
Dkk1 expression and MDSC accumulation. To test our hypothesis, we obtained tissue microarrays (TMAs) from 55
T1-T3 and stage I-II tumor tissues from pancreatic cancer
patients with no metastatic disease. The TMAs were blindly
scored for the presence of CD15+ infiltrates and Dkk1 expression.We found tumor tissues with high Dkk1 expression both
in the tumor cells and in the associated tumor stroma, and
others with low Dkk1 expression (Fig. 2 I). Nevertheless, we
observed that accumulation of CD15+ cells significantly correlated with increased Dkk1 expression (Spearman’s r = 0.27;
P < 0.05; Fig. 2 J). Future studies are required to measure
Dkk1 expression in the bone microenvironment and correlate this result with peripheral MDSCs. Collectively, these
findings support the hypothesis that Dkk1 induces MDSC
accumulation during tumor progression.

JEM Vol. 213, No. 5

Dkk1 neutralization affects tumor progression
in advanced cancer models
To further exploit the therapeutic effects of anti-Dkk1
treatment, we administered anti-Dkk1 to WT mice bearing
established s.c. tumors with already expanded MDSC population. 1 wk after 105 LLC s.c. injection, animals received
anti-Dkk1 or IgG control antibodies (20 mg/kg every other
day) for an additional 7 d. We observed a significant decrease in tumor growth (Fig. 4, A and B) and concomitant
reduction in MDSC percentage in the bone marrow, spleen,
and tumor site of anti-Dkk1–treated mice compared with
IgG controls (Fig. 4 C).
To determine whether Dkk1 neutralization would
exert significant antitumor effects in a mouse model of
pre-expanded MDSCs, we turned to PLCγ2−/− mice. We recently demonstrated that PLCγ2-null animals have increased
MDSC numbers and, in these mice, MDSCs are responsible
for the higher rate of tumor growth compared with WT mice
(Capietto et al., 2013). Most importantly, similarly to the cancer patients, MDSCs from PLCγ2−/− mice have significantly
lower β-catenin levels than WT MDSCs (Capietto et al.,
2013). Consistent with this observation, Dkk1 is significantly
up-regulated in the bone microenvironment of PLCγ2−/−
tumor-bearing mice compared with controls (Fig. 4 D).
To investigate whether Dkk1 neutralization would protect
PLCγ2−/− mice from tumor progression by reducing MDSC
numbers, 105 LLC cells were s.c. injected into PLCγ2−/− animals after the administration of anti-Dkk1 or IgG for 14 d.
Strikingly, Dkk1 neutralization dramatically reduced tumor
growth and percentage of MDSCs in the bone marrow,
spleen, and tumor site compared with IgG controls (Fig. 4,
E and F). Confirming that Dkk1 directly targets PLCγ2−/−
MDSCs, β-catenin levels in these cells were rescued by Dkk1
neutralization (Fig. 4 G). Importantly, the anti-Dkk1 treatment also affected MDSC functionality, as shown by a significant reduction in reactive oxygen species (ROS) and nitric
oxide (NO) production in PLCγ2−/− MDSCs isolated from
anti-Dkk1–treated mice compared with MDSCs from IgG
controls (Fig. 4, H and I).
Together, these results indicate that anti-Dkk1 reduces
established tumor growth and exerts antitumor effects in
831
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Dkk1 neutralization decreases tumor
growth and MDSC numbers
To demonstrate that Dkk1 contributes to MDSC accumulation in vivo by reducing β-catenin levels in these cells,
WT mice were s.c. injected with 105 LLC, a tumor cell
line which induces up-regulation of Dkk1 and increases
MDSC numbers during tumor progression (Fig. 1; Capietto
et al., 2013). Tumor-bearing mice were then administered
anti-Dkk1 or IgG as a control (20 mg/kg) three times per
week for 2 wk. Strikingly, we observed a significant decrease
in tumor growth and size after anti-Dkk1 treatment compared with IgG control (Fig. 3, A and B). In support of
our hypothesis, the percentages of Gr1+/CD11b+ MDSCs
in the bone marrow, spleen, and tumor were significantly
reduced (Fig. 3 C), and β-catenin expression was rescued
in MDSCs isolated from anti-Dkk1–treated mice compared
with IgG controls (Fig. 3 D).
MDSCs are potent suppressors of antitumor T cell responses. To determine whether Dkk1 neutralization is sufficient to restore T cell infiltration in the tumor stroma, we
measured by FACS the percentage of CD4+ and CD8+ T cells
in the tumor-bearing mice treated every other day with the
anti-Dkk1. Consistent with a reduction in MDSC numbers,
we found that the percentages of CD4+ and CD8+ T cells were
increased in anti-Dkk1–treated mice versus controls (Fig. 3 E).
MDSCs have been shown to increase with tumor burden in several models. Therefore, to ask if changes in MDSCs
were caused by Dkk1 levels and not primary tumor size, we
examined MDSCs in anti-Dkk1–treated and IgG control
mice that were sacrificed 7 d after tumor injection, when
no detectable differences in tumor growth were yet observed
(Fig. 3 F). Confirming the similar tumor size detected by
caliper measurements, the weight of the excised tumors was
not different between the two groups (Fig. 3 F). Nevertheless, a significant decrease in MDSC percentage was already
evident at this time point in the bone marrow, spleen, and
tumor site (Fig. 3 G). These data indicate that the effects of

anti-Dkk1 on MDSCs precede the effects of the neutralizing
antibody on tumor growth.
Because we found that Dkk1 levels were elevated in circulation and in the bone microenvironment of mice bearing
B16 tumors (Fig. 1, E and G), we next asked if Dkk1 neutralization could also exert antitumor effects in this model.
Indeed, anti-Dkk1 was sufficient to significantly reduce B16
subcutaneous tumor growth (Fig. 3 H). As with the LLC
tumor model, the percentage of MDSCs was significantly
reduced in the bone marrow and spleen by the anti-Dkk1
treatment (Fig. 3 I).Together, these data show that Dkk1 neutralization reduces tumor growth and MDSC accumulation
during tumor progression.

mouse models of preexpanded MDSCs by decreasing MDSC
numbers and functionality.
MDSCs are a direct target of anti-Dkk1 treatment
To determine whether Dkk1 neutralization reduces tumor
growth by increasing β-catenin levels in MDSCs, and not
by targeting other cell populations, we analyzed the effects
of anti-Dkk1 treatment in β-catenin–floxed mice expressing the Cre recombinase under the control of Lysozyme M
(LysM-Cre/β-cateninflox/flox; herein defined as βcatcKo). We
832

previously demonstrated that MDSCs from βcatcKo mice do
not express β-catenin (Capietto et al., 2013). LLC cells were
injected s.c. into βcatcKo animals, followed by anti-Dkk1 or
IgG treatment, three times a week for 2 wk. Tumor growth
was followed by caliper measurements at indicated days and
the tumor mass was resected and weighed. In contrast to WT
mice, anti-Dkk1 treatment did not affect the growth or size
of the LLC tumors (Fig. 5 A, B); more importantly, Dkk1
neutralization did not reduce the percentage of MDSCs
in the bone marrow, spleen, or tumor site of βcatcKo aniRole of Dkk1 in cancer | D’Amico et al.
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Figure 3. Dkk1 neutralization decreases tumor growth and MDSC expansion. (A) Anti-Dkk1 or IgG control antibodies (20 mg/kg, three times per
week) were administered for 2 wk into WT mice s.c. injected with 105 LLC cells. Tumor growth was evaluated by caliper measurements at indicated days.
Mean ± SD (n = 7) is shown. Data are reported from one of three similar independent experiments. *, P < 0.05; **, P < 0.01. (B) 14 d after tumor injection,
the tumors shown in A were resected. One representative image is shown. (C) Percentage of MDSCs in the bone marrow, spleen, and tumor was analyzed by
FACS using anti-Gr1 and anti-CD11b staining. Results represent means ± SD (n = 7). One representative experiment of three is shown. *, P < 0.05. (D) MDSCs
were isolated from the bone marrow of no tumor or tumor-bearing WT mice receiving IgG control or anti-Dkk1 treatment and subjected to Western blot
analysis to measure β-catenin protein levels. β-Actin was used as loading control. One representative Western blot from three independent experiments
is shown. (E) CD4+ and CD8+ T cell percentage was analyzed by FACS in excised tumors from WT mice treated with anti-Dkk1 or IgG control. Bar graphs
show mean ± SD (n = 7). *, P < 0.05. One representative experiment of three is shown. (F) WT mice s.c. inoculated with 105 LLC cells were treated with anti-Dkk1 or IgG control starting 1 wk after tumor inoculation. After 7 d of treatment, the animals were sacrificed and the tumor was resected and weighed.
Results represent mean ± SD (n = 5). (G) Percentage of MDSCs (Gr1+/CD11b+) from bone marrow, spleen, and tumor of mice in F were then analyzed by
FACS staining. Results represent mean ± SD (n = 5). *, P < 0.05. (H) Tumor growth in mice inoculated with 105 B16 cells treated with IgG or anti-Dkk1 was
evaluated by caliper measurements for the indicated days. Mean ± SD (n = 5) is shown. Data reported from one of three similar independent experiments.
**, P < 0.01. (I) Percentage of Gr1+/CD11b+ MDSC from bone marrow and spleen of mice treated as in H were analyzed by FACS staining. Results represent
mean ± SD (n = 5). **, P < 0.01.

mals (Fig. 5 C). Consistent with our previous observation
showing that the expression of a constitutively active form
of β-catenin in myeloid cells limits tumor growth by reducing MDSC numbers and functionality (Capietto et al.,
2013), we now demonstrate that Dkk1 neutralization exerts
profound antitumor effects by restoring β-catenin levels in
the myeloid compartment.
To further establish that the Dkk1-neutralizing antibody targets MDSCs, and not other immune cell populations,
we injected 105 LLC into WT mice receiving anti-Gr1 (12.5
mg/kg) to deplete MDSCs in the presence or in the absence
of anti-Dkk1. Mice receiving IgG were used as controls. As
shown previously, anti-Gr1 exerts significant antitumor effects (Mundy-Bosse et al., 2011). The reduction in tumor
growth after anti-Gr1 treatment was similar to that observed
in mice treated with anti-Dkk1 (Fig. 5 D). No further decrease in tumor growth was noted in mice receiving both
JEM Vol. 213, No. 5

anti-Gr1 and anti-Dkk1 compared with each treatment alone
(Fig. 5 D). Consistent with our hypothesis that anti-Dkk1
targets MDSCs, Dkk1 neutralization induced a similar reduction in the percentage of MDSCs at tumor site to that
observed in mice treated with anti-Gr1 alone or anti-Gr1
plus anti-Dkk1 (Fig. 5 E). These results demonstrate that the
antitumor effects of Dkk1 neutralization overlap with those
of the anti-Gr1, further implicating Dkk1 as an important
regulator of tumor-induced MDSCs.
Dkk1 controls MDSC immune suppressive effects
Because one of the best-characterized functions of MDSCs is
to actively suppress cytotoxic T cell responses, we examined
whether T cells were important players in mediating the antitumor effects of the anti-Dkk1. To this end, we injected 105
LLC cells s.c. into Nude mice, which lack T cell populations,
and administered anti-Dkk1 or IgG antibodies as described in
833
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Figure 4. Dkk1 neutralization reduces tumor progression in tumor models of preexpanded MDSCs. (A and B) 105 LLC cells were s.c. injected in WT
mice and anti-Dkk1 and IgG treatments (20 mg/ml) were administered 7 d after tumor inoculation and treated for seven additional days. Tumor growth
was assessed by caliper measurements. Mean ± SD (n = 5) is shown. *, P < 0.05. (B) Representative image of tumors as shown in A. (C) Percentage of Gr1+/
CD11b+ MDSCs isolated from bone marrow, spleen, and tumor of mice treated as in A was determined by FACS. Results represent means ± SD (n = 5). *, P <
0.05. (D) Dkk1 mRNA expression in crushed bones devoid of bone marrow cells of PLCγ2−/− mice s.c. injected with 105 LLC cells. Mean ± SD (n = 5) is shown.
**, P < 0.01. (E) Tumor growth in PLCγ2−/− mice injected s.c. with 105 LLC cells and treated with anti-Dkk1 or IgG control (20 mg/kg) three times per week
for 2 wk starting at time of LLC injection. Tumor size was determined by caliper measurements. n = 4, representative of three independent experiments. *, P
< 0.05; **, P < 0.01. (F) Percentage of Gr1+/CD11b+ MDSCs isolated from bone marrow, spleen, and tumor of mice treated as in E was determined by FACS.
Mean ± SD. n = 4; representative of three independent experiments. *, P < 0.05. (G) β-Catenin protein levels were measured by Western blot in PLCγ2−/−
MDSCs isolated from the bone marrow of no tumor or tumor-bearing mice after IgG and anti-Dkk1 treatment. β-Actin was used as loading control. One
representative Western blot is shown. (H and I) ROS and NO levels measured in PLCγ2−/− MDSCs isolated from tumor-bearing mice treated with anti-Dkk1
or IgG as control. Data are reported from one of two independent experiments. Mean from biological triplicates ± SD. *, P < 0.05; **, P < 0.01.

the Materials and methods.We found no differences in tumor
growth between anti-Dkk1 and IgG control-treated mice at
late stages of tumor progression (Fig. 6 A). This finding indicates that T cells are required for anti-Dkk1 long-term antitumor effects, leading to the hypothesis that Dkk1 targeting
may reduce MDSC immune suppressive functions.
ROS production is one of the mechanisms attributed
to MDSC ability to suppress T cell responses. To determine
whether Dkk1 directly affects MDSC functionality, we measured ROS levels in MDSCs isolated from WT mice and
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DISCUSSION
This study demonstrates that Dkk1, an antagonist of the
Wnt–β-catenin pathway, supports tumor progression by creating an immune suppressive environment where tumor cells
can grow unabated. We show that Dkk1 neutralization confers protection from tumor growth by reducing the generation and the T cell suppressive effects of MDSCs. To our
Role of Dkk1 in cancer | D’Amico et al.
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Figure 5. Dkk1 neutralization loses its antitumor effects in βcatcko
mice and after MDSC depletion. (A and B) 105 LLC cells were s.c. injected
in βcatcKo mice and anti-Dkk1 or IgG as control (20 mg/kg) were administered three times per week. Tumor growth was followed by caliper measurements (A) and, 2 wk later, tumors were resected and weighed (B). Mean
± SD (n = 8). Data are reported from one of two independent experiments.
n.s., not significant. (C) Percentage of Gr1+/CD11b+ MDSCs isolated from
bone marrow, spleen, and tumor of mice in A was determined by FACS. Results represent means ± SD (n = 8). One representative experiment of two
is shown. n.s., not significant. (D) 105 LLC cells were s.c. injected in WT mice,
and IgG, anti-Dkk1 (20 mg/kg), anti-Gr1 (12.5 mg/kg), or anti-Dkk1 plus
anti-Gr1 were administered three times per week. Tumor growth was followed by caliper measurements. Mean ± SD (n = 6/7 mice group). P-values
are shown in table. (E) Percentage of Gr1+/CD11b+ MDSCs in tumors from
mice treated as in D was determined by FACS. Results represent means ±
SD (n = 6/7). *, P < 0.05; ***, P < 0.001. n.s., not significant.

stimulated in vitro with rDkk1 (1 µg/ml). Consistent with
our hypothesis, rDkk1 significantly increased ROS production by MDSCs (Fig. 6 B).
Next, to test whether anti-Dkk1 treatment impacts
MDSC functionality, we examined the ability of MDSCs
isolated from tumor-bearing mice treated with anti-Dkk1
or IgG to suppress T cell proliferation ex vivo. CSFE-labeled
splenocytes from naive WT mice were incubated with anti-CD3 (10 µg/ml) to induce mitogen-driven CD8+ T cell
proliferation in the presence of MDSCs isolated from tumorbearing mice treated with anti-Dkk1 or IgG control. Three
different ratios of MDSCs/splenocytes (1:10, 1:5, and 1:1)
were tested and proliferation of targeted CD8+ T cells was
measured in terms of CFSE dilution by FACS analysis 72 h
later. MDSCs isolated from anti-Dkk1–treated WT mice displayed reduced T cell immune suppressive effects compared
with MDSCs from IgG controls (Fig. 6 C). Consistent with
the in vitro observations, increased percentage of T cells in
the spleen and primary tumor was also observed in vivo in
tumor-bearing WT mice after treatment with anti-Dkk1
(Fig. 6 D and 3 E). To further evaluate whether the number
of activated T cells is also increased upon treatment with antiDkk1, we measured the percentage of activated CD44hi
CD62Llow and memory CD44hiCD62Lhi, splenic CD4+ and
CD8+ T cells in WT mice 14 d after tumor injection. Our
data show higher percentage of activated and memory T cells
in mice treated with anti-Dkk1 (Fig. 6, E and F).
As previously shown, PLCγ2−/− MDSCs have very
strong immunosuppressive effects (Capietto et al., 2013).
Treatment with anti-Dkk1 significantly reduced PLCγ2−/−
MDSC ability to suppress T cell proliferation ex vivo
(Fig. 6 G), and increased CD4+ and CD8+ T cell percentages in the spleen of PLCγ2−/− tumor-bearing mice in vivo
(Fig. 6 H). These results are consistent with reduced ROS
and NO levels observed in PLCγ2−/− MDSCs isolated from
anti-Dkk1–treated mice (Fig. 4 H, I).
In contrast, Dkk1 neutralization did not affect the immunosuppressive capacities of βcatcKo MDSCs, as shown by
a similar T cell proliferation rate by βcatcKo MDSCs isolated
from IgG and anti-Dkk1–treated mice (Fig. 6 I). In agreement with the in vitro findings, anti-Dkk1 treatment failed
to increase the T cell percentage in the spleen of tumorbearing βcatcKo (Fig. 6 J).
Collectively, these results indicate that Dkk1 exerts immune suppressive effects by targeting β-catenin levels in
MDSCs, thus controlling MDSC accumulation and their ability
to suppress T cell activation and proliferation.
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proliferation assay was performed as in C using WT splenocytes co-cultured with PLCγ2−/− MDSCs. Bar graphs show mean ± SD of three independent experiments. *, P < 0.05. (H) Percentage of CD4+ and CD8+ T cells
in spleen of PLCγ2−/− tumor-bearing mice after anti-Dkk1 or IgG treatment
was measured by FACS. Bar graphs show mean ± SD (n = 3, representative
of three independent experiments). *, P < 0.05. (I) CD8+ T cell proliferation
assay as in C in the presence of βcatcKo MDSCs isolated from anti-Dkk1
and IgG antibody-treated mice. Bar graphs show mean ± SD. n = 3. (J) Percentage of CD4+ and CD8+ T cells in spleen of βcatcKo tumor-bearing mice
after anti-Dkk1Ab and IgG treatment was measured by FACS. Bar graphs
show mean ± SD (n = 8), representative of two independent experiments.
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Figure 6. Neutralization of Dkk1 decreases MDSC immune suppressive activity. (A) 105 LLC cells were s.c. injected in Nude mice and anti-Dkk1 or IgG as control (20 mg/kg) were administered three times per
week. Tumor growth was followed by caliper measurements. Mean ± SD
(n = 8). *, P < 0.05. (B) ROS production in Gr1+/CD11b+ cells from naive
WT mice and stimulated in vitro with rDkk1 for 24 h. Bar graphs show
mean ± SD of biological triplicates. Representative of two independent experiments. **, P < 0.01. (C) MDSCs, isolated from WT tumor-bearing mice
treated with anti-Dkk1 or IgG, were co-cultured for 3 d with CFSE-labeled
splenocytes from naive mice in the presence of anti-CD3 (10 µg/ml). CD8+ T
cell proliferation was measured in terms of CFSE dilution. Bar graphs show
mean ± SD of three independent experiments. *, P < 0.05. (D) Percentage of CD4+ and CD8+ T cells isolated from the spleen of WT tumor-bearing mice treated with anti-Dkk1 or IgG as control was analyzed by FACS.
Bar graphs show mean ± SD. n = 7. *, P < 0.05. (E and F) Percentage of
CD44highCD62Llow or CD44highCD62Lhigh CD4+ and CD8+ T cells in spleen of
WT tumor-bearing mice after anti-Dkk1 and IgG treatment was measured
by FACS. Bar graphs show mean ± SD (n = 7). *, P < 0.05. (G) CD8+ T cell

knowledge, this is the first study demonstrating that MDSCs
are a direct target of Dkk1, thus providing new insights as to
why elevated circulating levels of Dkk1 correlate with poor
prognosis in cancer patients.
In bone, Dkk1 negatively regulates osteoblast differentiation and enhances osteoclast formation, and therapies aimed
at targeting Dkk1 are in consideration for post-menopausal
osteoporosis (Zhang and Drake, 2012). High levels of Dkk1
are also observed in various cancer patients without detectable metastases to bone (Yamabuki et al., 2007; Liu et al.,
2014). However, the mechanism by which Dkk1 exerts its
protumorigenic effects has not been elucidated. Studies in
MM indicate that Dkk1 changes the bone microenvironment
by creating a hospitable niche that allows dissemination and
proliferation of tumor cells (Fowler et al., 2012). Interestingly, although administration of anti-Dkk1 reduces tumor
burden in vivo, the growth of MM cells is not affected in
vitro, suggesting that the bone microenvironment is the target of the anti-Dkk1 treatment rather than the MM tumor
cells (Yaccoby et al., 2007). In support of this assumption,
Dkk1 is found to be highly expressed by bone marrow stromal cells and knockdown of Dkk1 in these cells decreases
myeloma progression in mice (Fowler et al., 2012). These
studies support a model in which Dkk1 produced by bone
marrow stromal cells induces the activation of bone resorbing osteoclasts and the release of tumor-promoting factors
stored in the bone matrix that favor MM growth. However,
although it is certainly possible that osteoclasts mediate Dkk1
protumor effects through the release of latent factors present
in the bone matrix, this model does not explain why elevated
Dkk1 levels correlate with poor prognosis in cancer patients
with no detectable tumors in bone. Regulation of extraskeletal tumors by resorbing osteoclasts needs to be further investigated. Pharmaceutical activation of bone resorbing osteoclasts
enhances breast cancer growth in bone, but not outside the
bone (Yang et al., 2013). Similarly, RANKL, a potent stimulator of osteoclastogenesis, increases prostate cancer cell growth
in bone but not in soft tissues (Zheng et al., 2014).These data
suggest that the Dkk1’s protumor effects may not be solely
related to its ability to enhance osteoclast activities.
Our work demonstrates a previously unidentified immune modulatory role for Dkk1 as a key player in the accumulation and activation of immunosuppressive myeloid cells. By
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fects of systemic anti-Dkk1 administration are mediated by
the myeloid compartment.
We propose that MDSCs are the primary target of Dkk1.
MDSCs express LRP5/6 co-receptors. Induction of LRP5
and LRP6 transcripts is also observed in naive bone marrow–
derived Gr1+/CD11b+ cells cultured in vitro in the presence
of 10% serum from tumor-bearing mice. Most importantly,
these cells respond to rDkk1 with reduced β-catenin protein levels and β-catenin target gene expression. Although we
don’t currently know whether additional factors present in
the serum from the tumor-bearing mice are required to support a more robust response to rDkk1 in vitro, most likely
increased expression of the Dkk1 target receptors LRP5 and
LRP6 mediates these effects. Similar to the mouse model,
rDkk1 also directly targets human MDSCs by decreasing
mRNA expression levels of β-catenin target genes, which are
restored upon depletion of Dkk1 from the serum of cancer
patients. Furthermore, we also show that Dkk1 neutralization
does not exert additional antitumor effects in mice treated
with an anti-Gr1 to deplete MDSCs, suggesting that the two
antibodies target the same myeloid population. Notably, antiDkk1 and anti-Gr1 treatments induce a similar reduction in
tumor growth and MDSC numbers.
Whereas MDSCs are certainly a direct target of Dkk1,
we also observe that anti-Dkk1 antitumor effects depend on
T cells. Indeed, Dkk1 neutralization fails to reduce tumor
growth in Nude mice that lack T cells. This result, together
with the loss of antitumor effects in βcatcKo mice, suggests
that anti-Dkk1 protects from tumor growth by reducing
MDSC numbers at tumor site, and consequently restoring T
cell recruitment/activation. In support of this hypothesis, the
percentage of activated and memory T cells in animals treated
with an anti-Dkk1 was increased compared with IgG controls.
Very little is known about the regulation of Dkk1
during tumor progression. Here, we report that LLC and
B16 tumor cell lines do not express Dkk1 in vitro. However,
Dkk1 levels are significantly increased in circulation in LLC
and B16 tumor-bearing mice. Although we can detect Dkk1
expression at tumor site, Dkk1 mRNA levels in the bone
are 500-fold higher than in the tumor mass. This finding is
further supported by the elevated Dkk1 protein levels measured in the bone microenvironment of tumor-bearing mice
versus no tumor controls.This observation is very important
because it supports a prominent role for bone-derived Dkk1
and indicates that it exerts profound protumor effects, even
when tumors are located outside the bone. Human studies
have measured circulating Dkk1 levels, with several showing
increased Dkk1 expression in circulation and in the primary
tumors (Yamabuki et al., 2007; Liu et al., 2014). Bone expression of Dkk1 in cancer patients with no detectable tumors
in bone has never been evaluated. Future studies will have
to determine whether bone-derived Dkk1 correlates with
immune suppression in cancer patients and what are the paracrine factors that regulate Dkk1 expression in bone when the
tumor resides outside the bone.
Role of Dkk1 in cancer | D’Amico et al.
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using extraskeletal tumor models consisting of mice injected
subcutaneously with LLC or B16 tumor lines, we report that
neutralization of Dkk1 reduces tumor growth, limits MDSC
expansion, decreases MDSC immune suppressive effects and,
in turn, increases T cell numbers and activation in the spleen
and primary tumor. Importantly, we further demonstrate
that Dkk1 neutralization reduces growth of established tumors and also exerts potent antitumor effects in mice lacking
PLCγ2, which have increased numbers of MDSCs.
Decreased PLCγ2 and β-catenin levels have been
previously observed in patients with advanced cancer (Capietto et al., 2013). Mice lacking PLCγ2 have expanded
MDSC numbers with very low β-catenin expression, and
tumor growth is increased compared with WT animals. As
a consequence of the significant MDSC accumulation and
activation, PLCγ2−/− mice have impaired antitumor T cell
responses; however, adoptive T cell transfer has only limited
antitumor effects in these animals (Zhang et al., 2011), suggesting that MDSCs establish a very strong immune suppressive environment in these animals. We now demonstrate that
neutralization of Dkk1 exerts significant antitumor effects
in PLCγ2−/− mice by reducing MDSC accumulation and
functionality and consequently increasing the percentage of
T cells.This finding, in conjunction with the protective effect
of anti-Dkk1 treatment on established tumors, suggests that
an anti-Dkk1 could potentially be a useful antitumor therapy
for advanced cancer patients. Previous studies have shown expanded CD15+ MDSC population (Porembka et al., 2012)
with reduced β-catenin levels (Capietto et al., 2013) in pancreatic cancer.We now find a correlation between Dkk1 levels
and tumor-infiltrating CD15+ cells in these patients. Further
studies, however, are needed to determine whether bonederived Dkk1 might have a stronger correlation with MDSC
numbers and if Dkk1 induces CD15+ cell accumulation in
other types of cancer, where Dkk1 levels are low at tumor site.
The finding that an anti-Dkk1 suppresses growth
of tumors residing outside the bone is an important observation. β-catenin is a known regulator of tumor cell
proliferation. Systemic administration of anti-Dkk1 in tumorbearing mice could, therefore, also target the tumor cells
and enhance their proliferation by increasing β-catenin expression. Although certainly possible for some tumors more
strictly dependent on β-catenin levels for their growth, our
data demonstrate that restoring the expression of β-catenin
in myeloid cells and, more specifically, in MDSCs, is sufficient to exert potent antitumor effects. These findings
are in agreement with the tumor phenotype of mice expressing a nondegradable form of β-catenin in myeloid
cells, which are protected from tumor growth as a result of
limited MDSC expansion (Capietto et al., 2013). Similarly,
we now show that Dkk1 neutralization increases β-catenin
expression in MDSCs and limits their ability to suppress
T cell proliferation. Importantly, the antitumor effects of the
neutralizing antibody are lost in mice lacking β-catenin in
myeloid cells. These data demonstrate that the antitumor ef-

In conclusion, our study demonstrates that Dkk1 is a
negative modulator of antitumor immune responses via targeting myeloid suppressor cells in both mice and humans. We
propose a model whereby an incipient tumor induces the expression of Dkk1 by bone-resident cells and, to a lesser extent,
in the primary tumor. Importantly, Dkk1 production by the
bone microenvironment drives MDSC accumulation during
tumor progression while Dkk1 expression by the tumor
stroma might control MDSC recruitment and immune suppressive functions at tumor site.

Antibody neutralization.Anti-Dkk1 neutralizing antibody
and IgG isotype control were provided by Amgen. Treatment
consisted of s.c. injections in the flank of mice of anti-Dkk1
and IgG control at dose of 20 mg/kg three times a week for
14 d. Anti-Gr1Ab was purchased from Bio X Cell and injected i.p. at a concentration of 12.5 mg/kg three times a
week for 2 wk. Recombinant mouse Dkk1 protein was purchased from R&D Systems and used at the concentration of
100 ng/ml for qRT-PCR analysis of β-catenin target genes or
1 µg/ml for ROS production.
Mouse Dkk1 ELISA assay.Dkk1 levels from serum and bone
marrow interstitial fluid of B16 and LLC tumor-bearing mice
or tumor-free animals were measured by ELISA according
to the manufacturer’s instructions (R&D Systems). In brief,
for measurements of Dkk1 in the bone marrow interstitial
fluid, tibias and femurs were collected and placed in a plate
with PBS until all bones were collected. The tibia and femur
from each leg were then spun in microcentrifuge tubes with
the tip cut off and placed inside a larger microcentrifuge
tube to collect the bone marrow. The bone marrow was suspended in 40 µl of PBS and centrifuged at 8,000 RPM for 5
JEM Vol. 213, No. 5

Flow cytometric analysis.Immediately upon sacrifice, singlecell suspensions were prepared from bone marrow, spleen, and
tumor. In brief, bone marrow cells were harvested from tibias
and femurs by centrifugation, whereas spleens were mechanically dissociated and individual cell suspensions were obtained through a 70-µm cell strainer. Tumor tissues were
minced, and then digested with 3.0 mg/ml collagenase A
(Roche) and 50 U/ml DNase I (Sigma-Aldrich) in serum
free media for 30 min at 37°C. Cells were filtered through
40-µm nylon strainers (Thermo Fisher Scientific), and washed
twice in PBS with 2% FBS. Red blood cells were then removed with red blood cell lysis buffer (Sigma-Aldrich). Cells
were washed once and stained in PBS with 0.5% FBS with
the following anti–mouse antibodies: allophycocyanin (APC)conjugated α-Gr1Ab and eFluor450-conjugated anti-CD44
(eBioscience), phycoerythrin (PE)-conjugated antibody to
CD11b, APC-conjugated anti-CD8α, and FITC-conjugated
anti-CD4 (BD), Brilliant Violet 605 anti-CD62L (BioLegend). The respective isotype-matched conjugated controls
were purchased from eBioscience and BD, respectively. Corresponding isotope controls yielded no significant staining.
Acquisition was performed on a FACSCalibur and the dedicated software CellQuest (BD). Data were analyzed with
FlowJo 7.5.5 software (Tree Star).
MDSC isolation.MDSCs were isolated from bone marrow
using the Myeloid-Derived Suppressor Cell Isolation kit
(Miltenyi Biotec), and >95% cell purity was confirmed by
flow cytometric analysis using anti-CD11b and anti-Gr1.
When indicated, Gr1+/CD11b+ cells were isolated from
naive mice and cultured in vitro in medium supplemented
with 10% serum from tumor-bearing mice, 10 ng/ml
GMCSF, and 40 ng/ml IL-6.
Human PBMCs from healthy donors were obtained at
Washington University. In brief, informed consent was prospectively obtained from all the blood donors according to an
institutionally approved Human Studies Committee Protocol. Peripheral blood samples were collected in vacuum tubes
containing EDTA (BD). PBMCs were isolated by Ficolldensity centrifugation and frozen in DMSO with 10% FBS.
For the experiment, thawed cells were washed and prepared
for cell isolation using CD33 microbeads with MiniMACS
columns according to the manufacturer’s protocol (Miltenyi
Biotec). Purity was confirmed by flow cytometry (>95%).
RNA isolation was immediately performed.
ROS and NO production.For ex vivo ROS production,
MDSCs were isolated from LLC tumor-bearing mice treated
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MATERIALS AND METHODS
Animals and tumor models.Animals were housed in a pathogen-free animal facility at Washington University (St. Louis,
MO). 6–8-wk-old littermate mice were used in all experiments according to protocols approved by the Institutional
Animal Care and Use Committee chaired by D.R. Abendschein. WT, PLCγ2−/−, and LysM-Cre/β-cateninflox/flox
(βcatcKo) mice were on C57BL/6 background and were previously described (Capietto et al., 2013). Nude mice were
purchased from The Jackson Laboratory. All in vivo figures are
shown as representative experiments.
LLC (C57BL/6 mouse LLC) and B16 (C57BL/6
mouse melanoma cells) were cultured at 37°C in complete
media (DMEM supplemented with 2 mM l-glutamine, 100
µg/ml streptomycin, 100 IU/ml penicillin, and 1 mM sodium
pyruvate) containing 10% FBS.To establish tumors, B16 (105)
and LLC (105) tumor cells were suspended in PBS and inoculated s.c. in the flank of sex- and age-matched mice. Tumor
measurements were performed every 2 or 3 d with a caliper
and volumes were calculated using the following formula:
V = ½(length [mm] × width [mm] 2).

min to separate the marrow cells from the supernatant, and
then 10 µl of supernatant from each set of legs were used for
the ELISA assay. Final concentration of Dkk1 in the bone
marrow interstitial fluid was calculated by taking into consideration the volume of PBS used to dilute the bone marrow from each set of legs.

T cell suppression assay.Freshly isolated splenocytes (5 × 106
cells/ml) from WT mice were depleted of red cells with Red
Blood Cells Lysis Buffer (Sigma-Aldrich) and labeled with
CFSE (1 µM; Molecular Probes) for 10 min at 37°C and
washed with fresh culture media. Splenocytes were stimulated
with anti-CD3 (10 µg/ml) in the presence of WT, PLCγ2−/−,
or βcatcKo MDSCs isolated from tumor-bearing mice treated
with anti-Dkk1 or IgG antibodies. Different CFSE-labeled
splenocyte/MDSC ratios were used (1:10, 1:5, and 1:1). Proliferation of CD8+ T cells, in terms of CFSE dilution, was
determined by FACS. Data are expressed as the percentage of
proliferation of stimulated CD8+ CFSE+ T cells. Each experiment was performed in triplicate.
Western blotting.MDSCs isolated from the bone marrow of
tumor-bearing mice were lysed with RIPA buffer (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS,
0.5% sodium deoxycholate, 1 mM EDTA, and 10% glycerol)
supplemented with protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). Equal amounts of total protein lysates were subjected to 8% SDS-PAGE gel and
transferred to PVDF membranes. Membranes were blocked
in 5% BSA in PBS/Tween-20 for 1 h, and then probed with
the appropriate specific primary antibody overnight at 4°C.
Membranes were washed and incubated for 2 h at room temperature with secondary antibody-conjugated with peroxidase. Results were visualized by chemiluminescence detection
using a SuperSignal West Dura Extended Duration Substrate
(Thermo Fisher Scientific). An antibody against total βcatenin was obtained from Cell Signaling Technology. Equal
loading was assessed using anti–β-actin from Sigma-Aldrich.
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Semi-quantifications of protein were determined using GeneTools software (Syngene).
IHC analysis.Tissue sections from LLC and B16 s.c. tumors
or pancreas from animals that express an oncogenic form of
RAS and develop spontaneous pancreatic cancer (KPC mice:
p48-CRE/Lox-stop-lox KrasG12D/+ p53flox/+) were used
for Dkk1 IHC analyses. Paraffin sections were deparaffinized
in serial changes with decreasing ethanol (100, 95, 70, and
50%), deionized with H2O, and rinsed in PBS. Tissue sections were submerged in citrate buffer (10 mM sodium citrate and 0.05% Tween 20, pH 6), and antigen retrieval was
performed in a decloaking chamber (Biocare Medical). The
sections were washed in running deionized water and rinsed
in PBS, blocked for 30 min at room temperature in blocking
buffer (5% normal goat serum, BSA, and PBS), and stained
with anti-Dkk1 primary antibody (Santa Cruz Biotechnology, Inc.; clone H-120; 1:100) diluted in antibody diluent
overnight at 4°C. The day after washing, a biotinylated secondary antibody was applied to the slides for 30 min at room
temperature in a humidified chamber, after SA-HRP incubation (Perkin Elmer) for an additional 30 min. Staining was
developed using DAB after 3 min of incubation. The tissue
sections were mounted on coverslips with Vectashield Hard
Mounting Media (Vector Labs).
Pancreatic cancer TMA cohort and analysis.TMA studies
were conducted on a patient cohort constructed from 60
cases of invasive pancreatic ductal adenocarcinoma diagnosed at the Department of Pathology, Washington University (Mitchem et al., 2013; Zhu et al., 2014). Patients had not
received neoadjuvant therapy, and they underwent pancreaticoduodenectomy, which was typically followed by adjuvant chemotherapy.The ethical committee at the Washington
University School of Medicine approved this study. To assemble TMAs, clearly defined areas of tumor tissue were demarked on a slide with a fresh tissue section from the paraffin
block. Two biopsies (1.0 mm diam) were taken from each
donor paraffin block corresponding to the marked area. For
immunohistochemical analyses, 4.0-mm paraffin sections
were used. Fully automated image acquisition was used for
the results presented in this study. The Aperio ScanScope
XT Slide Scanner (Aperio Technologies) system was used to
capture whole slide digital images with a 20× objective.
Slides were de-arrayed to visualize individual cores using
Spectrum software (Aperio). CD15+ leukocytes were quantitated using a modified nuclear/lymphocyte algorithm in
the spectrum software, and Dkk1 was quantitated as total
pixel density. The highest value to each TMA spot was
assigned to each patient.
Real-time PCR.Total RNA was extracted with TRIzol (Invitrogen) and quantified on a ND-1000 spectrophotometer
(NanoDrop Technologies). The cDNA was synthesized with
1 µg RNA using RNA to cDNA EcoDry Premix (oligo dT)
Role of Dkk1 in cancer | D’Amico et al.
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with anti-Dkk1 neutralizing antibody or IgG control for 14
d. 105 cells were then incubated for 30 min in the presence of
oxidation-sensitive dye DCFDA (3 µM). MDSCs were stained
with anti-Gr1 and CD11b antibodies and ROS production in
the cells was evaluated FACS analysis.
For in vitro ROS production, 105 Gr1+/CD11b+ cells
were isolated from naive mice and cultured in RPMI 1640
supplemented with 10 ng/ml GMCSF + 40 ng/ml IL-6, and
then stimulated with 1 µg/ml rDkk1 for 24 h in the presence
of PMA (300 nM; Sigma-Aldrich) for the last 30 min. ROS
detection by FACS was performed as described above.
For NO levels, 105 MDSCs isolated from tumor-bearing
mice receiving anti-Dkk1 or IgG antibodies were cultured in
RPMI 1640 media supplemented with 10 ng/ml GM-CSF +
40 ng/ml IL-6 and stimulated with 1 µg/ml LPS for 24 h.
100 µl of culture supernatants were incubated for 10 min
at room temperature with Greiss reagent (1% sulfanilamide,
0.1% N-[1-naphthyl]ethyl-enediamine, and 5% H3PO4) to
measure the nitrite concentrations.The absorbance at 540 nm
was measured using a microplate reader (Bio-Tek). Nitrite
concentrations were determined by comparing the absorbance values from the samples to a standard curve generated
by serial dilutions of sodium nitrite (0.25 mM).

Statistical analysis.Experiments were done in triplicate
and analyzed using the Student’s t test. In calculating twotailed significance levels for equality of means, equal variances were assumed for the two populations. In some
experiments, analysis of variance (ANOVA), including the
Bonferroni’s multiple-comparison test, was used. Results
were considered significant at P < 0.05.
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